<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39299663</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8511</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</Title><ISOAbbreviation>J Stroke Cerebrovasc Dis</ISOAbbreviation></Journal><ArticleTitle>Prevalence and determinant of long-term Post-COVID conditions among stroke survivors in the United States.</ArticleTitle><Pagination><StartPage>108007</StartPage><MedlinePgn>108007</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jstrokecerebrovasdis.2024.108007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1052-3057(24)00451-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persistent post-COVID conditions (PCCs) have become inevitable challenges for individuals who have survived COVID. The National Research Plan on Long COVID-19 underscores the priority of addressing post-COVID conditions (PCCs) within specific subgroups of the United States (US) population. This study aimed to investigate the prevalence and factors associated with PCCs among stroke survivors in the US.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In this retrospective cross-sectional study, we utilized the Behavioral Risk Factor Surveillance System (BRFSS) 2022 dataset. First, we identified respondents with a positive history of both COVID-19 and stroke. Subsequently, we categorized these respondents based on whether they experienced PCCs and conducted a comparative analysis of their characteristics. Additionally, our study included a comparison of our findings with those among individuals who have survived myocardial infarction (MI) and cancer.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3999 stroke, 5406 MI, and 10551 cancer survivors were included. The estimated prevalence of PCCs among stroke survivors was 30.6 %, compared to 22.4 %, 29.2 %, and 24.6 % among non-stroke (p &lt; 0.001), MI, and cancer survivors, respectively. Fatigue, dyspnea, and taste/smell loss were the most common primary symptoms. In multivariate regression analysis, female sex (adjusted odds ratio (aOR):1.62, 95 %CI:[1.17-2.24]), stroke-belt residence (aOR:1.67, 95 %CI: [1.13-2.46]), pulmonary disease (aOR:2.12, 95 %CI:[1.53-2.92]), and depression (aOR:1.55, 95 %CI: [1.1-2.2]) were independent factors associated with higher odds of PCCs among stroke survivors. Additionally, age above 64 years was associated with lower odds of PCCs (aOR:0.6, 95 %CI: [0.41-0.86]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study highlights a considerable prevalence of PCCs among stroke survivors, particularly among younger women and individuals with other chronic conditions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hejazian</LastName><ForeName>Seyyed Sina</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA. Electronic address: sina.hej95@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadr</LastName><ForeName>Alireza Vafaei</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, 17033, USA. Electronic address: asadr@pennstatehealth.psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahjouei</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: sshimashah@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Ajith</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA. Electronic address: avemuri@pennstatehealth.psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shouhao</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, 17033, USA. Electronic address: szhou1@pennstatehealth.psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abedi</LastName><ForeName>Vida</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, 17033, USA. Electronic address: vabedi@pennstatehealth.psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zand</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA. Electronic address: ramin.zand@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Stroke Cerebrovasc Dis</MedlineTA><NlmUniqueID>9111633</NlmUniqueID><ISSNLinking>1052-3057</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040343" MajorTopicYN="N">Behavioral Risk Factor Surveillance System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073116" MajorTopicYN="N">Cancer Survivors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Post-COVID conditions</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>19</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39299663</ArticleId><ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2024.108007</ArticleId><ArticleId IdType="pii">S1052-3057(24)00451-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>